1. Home
  2. NAC vs ZYME Comparison

NAC vs ZYME Comparison

Compare NAC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Quality Municipal Income Fund

NAC

Nuveen California Quality Municipal Income Fund

HOLD

Current Price

$11.72

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.00

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAC
ZYME
Founded
1998
2003
Country
France
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
1998
2022

Fundamental Metrics

Financial Performance
Metric
NAC
ZYME
Price
$11.72
$23.00
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
335.6K
510.3K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
4.33%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
$105,965,000.00
Revenue This Year
N/A
$183.10
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
38.87
52 Week Low
$10.94
$11.86
52 Week High
$12.25
$29.75

Technical Indicators

Market Signals
Indicator
NAC
ZYME
Relative Strength Index (RSI) 26.23 41.61
Support Level $11.64 $22.20
Resistance Level $12.04 $23.66
Average True Range (ATR) 0.08 0.86
MACD -0.04 -0.26
Stochastic Oscillator 0.05 12.47

Price Performance

Historical Comparison
NAC
ZYME

About NAC Nuveen California Quality Municipal Income Fund

Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: